TITLE

Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C

AUTHOR(S)
Tamura, Yasushi; Yamagiwa, Satoshi; Aoki, Yohei; Kurita, So; Suda, Takeshi; Ohkoshi, Shogo; Nomoto, Minoru; Aoyagi, Yutaka; Niigata Liver Disease Study Group
PUB. DATE
November 2009
SOURCE
Digestive Diseases & Sciences;Nov2009, Vol. 54 Issue 11, p2530
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
The association between serum alpha-fetoprotein (AFP) levels during and after interferon (IFN) therapy and the development of hepatocellular carcinoma (HCC) was evaluated in patients with chronic hepatitis C (CHC). A total of 263 patients treated by IFN with or without ribavirin were enrolled in the study. Serum AFP levels during and after IFN therapy were investigated retrospectively, and statistical analysis was performed to identify the factors associated with HCC development. During IFN therapy, serum AFP levels significantly decreased, regardless of virologic response to treatment. Increased serum AFP levels (>or=10 ng/ml) at the end of IFN therapy (EOT) was a close-to-significant variable affecting the development of HCC (P = 0.057), and a significantly higher cumulative incidence of HCC was seen in patients with increased serum AFP levels at EOT (P = 0.021). Serum AFP level at EOT is a possible predictor of HCC in CHC patients after IFN therapy.
ACCESSION #
44645829

 

Related Articles

  • Vitamin D and IL28B Genotyping as Predictors for Antiviral Therapy: A Retrospective Study in Egyptian HCV Genotype 4a. Abdelkader, Nadia Abdelaaty; Abdelmoniem, Soha Saoud; Sabry, Dina; Abdelbaky, Amin Mohamad; Mahdy, Maram M.; Zaky, Eman; Saad, Wessam Elsayed // Tropical Journal of Pharmaceutical Research;Oct2014, Vol. 13 Issue 10, p1725 

    Purpose: To evaluate the role of pre-treatment vitamin D serum level and interleukin28B (IL28B) (rs 12979860) polymorphism in chronic hepatitis C (CHC) genotype 4a patients treated with pegylated interferon a2-A and ribavirin (peg IFN+RBV) as predictors of response. Methods: A retrospective...

  • Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. Heidrich, Benjamin; Wiegand, Steffen B.; Buggisch, Peter; Hinrichsen, Holger; Link, Ralph; Möller, Bernd; Böker, Klaus H. W.; Teuber, Gerlinde; Klinker, Hartwig; Zehnter, Elmar; Naumann, Uwe; Busch, Heiner W.; Maasoumy, Benjamin; Baum, Undine; Hardtke, Svenja; Manns, Michael P.; Wedemeyer, Heiner; Petersen, Jörg; Cornberg, Markus // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Evidence based clinical guidelines are implemented to treat patients efficiently that include efficacy, tolerability but also health economic considerations. This is of particular relevance to the new direct acting antiviral agents that have revolutionized treatment of chronic hepatitis C. For...

  • Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. Moon, Chansoo; Jung, Kyu; Kim, Do; Baatarkhuu, Oidov; Park, Jun; Kim, Beom; Kim, Seung; Ahn, Sang; Han, Kwang-Hyub // Digestive Diseases & Sciences;Feb2015, Vol. 60 Issue 2, p573 

    Background: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients Methods: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to...

  • Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. Wiegand, Steffen B.; Heidrich, Benjamin; Susser, Simone; Rogalska-Taranta, Magdalena; Petersen, Jörg; Böker, Klaus H. W.; Grigorian, Natalia; Link, Ralph; Naumann, Uwe; John, Christine; Lueth, Stefan; Malfertheiner, Peter; Manns, Michael P.; Wedemeyer, Heiner; Sarrazin, Christoph; Cornberg, Markus // PLoS ONE;12/23/2015, Vol. 10 Issue 12, p1 

    Background: SNPs near the interferon lambda (IFNL) 3 gene are predictors for sustained virological response (SVR) in patients with chronic hepatitis C genotype (GT) 1. In addition, a dinucleotide frame shift in ss469415590 was described, which generates IFNL4. In this study, we compared the...

  • Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response. PINZONE, M. R.; ZANGHÌ, A. M.; RAPISARDA, L.; D'AGATA, V.; BENANTI, F.; SPARTÀ, D.; NUNNARI, G.; CACOPARDO, B. // European Review for Medical & Pharmacological Sciences;2014 Supplement2, Vol. 18, p11 

    INTRODUCTION: Hepatitis C virus (HCV) infection is a common cause of chronic liver disease and hepatocellular carcinoma (HCC). The prevalence of HCC significantly declines among patients achieving a sustained virological response (SVR) after antiviral therapy with pegylated(PEG)-interferon (IFN)...

  • Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Hézode, Christophe; Hirschfield, Gideon M.; Ghesquiere, Wayne; Sievert, William; Rodriguez-Torres, Maribel; Shafran, Stephen D.; Thuluvath, Paul J.; Tatum, Harvey A.; Waked, Imam; Esmat, Gamal; Lawitz, Eric J.; Rustgi, Vinod K.; Pol, Stanislas; Weis, Nina; Pockros, Paul J.; Bourlière, Marc; Serfaty, Lawrence; Vierling, John M.; Fried, Michael W.; Weiland, Ola // Gut;Jun2015, Vol. 64 Issue 6, p948 

    Objective: To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. Design: In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults with HCV genotype 1 (N=365) or 4 (N=30)...

  • Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. Federico, Alessandro; Masarone, Mario; Romano, Marco; Dallio, Marcello; Rosato, Valerio; Persico, Marcello // Hepatitis Monthly;Jun2015, Vol. 15 Issue 6, p1 

    Background: Standard [i.e. pegylated interferon (Peg-IFN) + ribavirin] treatment of hepatitis C virus (HCV)-related chronic hepatitis is associated with a sustained virological response (SVR) in 50 - 90% of patients. A rapid virological response (RVR) (i.e. negative HCV-RNA after 4 weeks of...

  • Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy. Sidharthan, Sreetha; Kohli, Anita; Sims, Zayani; Nelson, Amy; Osinusi, Anu; Masur, Henry; Kottilil, Shyam // Clinical Infectious Diseases;Jun2015, Vol. 60 Issue 12, p1743 

    Background: Hepatitis C virus (HCV) RNA loads serve as predictors of treatment response during interferon-based therapy. We evaluated the predictive ability of HCV RNA levels at end of treatment (EOT) for sustained virologic response (SVR12) during interferon-sparing direct-acting antiviral...

  • Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome. Yoo, Eric R.; Perumpail, Ryan B.; Cholankeril, George; Ahmed, Aijaz // Case Reports in Infectious Diseases;10/26/2016, p1 

    Patients with Down syndrome who received blood transfusions, likely in conjunction with cardiothoracic surgery for congenital heart disease and prior to the implementation of blood-donor screening for hepatitis C virus infection, face a substantial risk of acquiring the infection. In the past,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics